Cargando…

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

BACKGROUND: Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), there is limited real‐world evidence comparing their effectiveness according to patients’ clinical characteristics. This net...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Huang‐Chih, Wang, Chin‐Chou, Tseng, Chia‐Cheng, Huang, Kuo‐Tung, Chen, Yu‐Mu, Chang, Yu‐Ping, Lai, Chien‐Hao, Fang, Wen‐Feng, Lin, Meng‐Chih, Chuang, Hung‐Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643796/
https://www.ncbi.nlm.nih.gov/pubmed/37737541
http://dx.doi.org/10.1111/1759-7714.15111
_version_ 1785147162920747008
author Chang, Huang‐Chih
Wang, Chin‐Chou
Tseng, Chia‐Cheng
Huang, Kuo‐Tung
Chen, Yu‐Mu
Chang, Yu‐Ping
Lai, Chien‐Hao
Fang, Wen‐Feng
Lin, Meng‐Chih
Chuang, Hung‐Yi
author_facet Chang, Huang‐Chih
Wang, Chin‐Chou
Tseng, Chia‐Cheng
Huang, Kuo‐Tung
Chen, Yu‐Mu
Chang, Yu‐Ping
Lai, Chien‐Hao
Fang, Wen‐Feng
Lin, Meng‐Chih
Chuang, Hung‐Yi
author_sort Chang, Huang‐Chih
collection PubMed
description BACKGROUND: Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), there is limited real‐world evidence comparing their effectiveness according to patients’ clinical characteristics. This network meta‐analysis (NMA) compared survival outcomes among first‐line EGFR‐TKIs in different subgroups of East Asian patients with advanced NSCLC. METHODS: This NMA included real‐world observational studies reporting outcomes with TKIs in patients aged >65 years, with baseline brain metastasis, with different Eastern Cooperative Oncology Group (ECOG) statuses, or with different common EGFR mutation types. RESULTS: In patients with the EGFR L858R mutation, afatinib resulted in significantly longer progression‐free survival (PFS) than erlotinib (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.46–0.75) and gefitinib (HR: 0.41, 95% CI: 0.32–0.53). Similarly, in patients with the EGFR Del19 mutation, afatinib and erlotinib resulted in significantly longer PFS than gefitinib (HR: 0.48 with 95% CI: 0.33–0.71 and HR: 0.54 with 95% CI: 0.36–0.80, respectively). Moreover, afatinib resulted in significantly longer PFS than gefitinib in patients with brain metastasis (HR: 0.53, 95% CI: 0.33–0.87) or ECOG status 0–1 (HR: 0.37, 95% CI: 0.23–0.59). CONCLUSION: This NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0–1, and with baseline brain metastasis.
format Online
Article
Text
id pubmed-10643796
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-106437962023-11-15 Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs Chang, Huang‐Chih Wang, Chin‐Chou Tseng, Chia‐Cheng Huang, Kuo‐Tung Chen, Yu‐Mu Chang, Yu‐Ping Lai, Chien‐Hao Fang, Wen‐Feng Lin, Meng‐Chih Chuang, Hung‐Yi Thorac Cancer Original Articles BACKGROUND: Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), there is limited real‐world evidence comparing their effectiveness according to patients’ clinical characteristics. This network meta‐analysis (NMA) compared survival outcomes among first‐line EGFR‐TKIs in different subgroups of East Asian patients with advanced NSCLC. METHODS: This NMA included real‐world observational studies reporting outcomes with TKIs in patients aged >65 years, with baseline brain metastasis, with different Eastern Cooperative Oncology Group (ECOG) statuses, or with different common EGFR mutation types. RESULTS: In patients with the EGFR L858R mutation, afatinib resulted in significantly longer progression‐free survival (PFS) than erlotinib (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.46–0.75) and gefitinib (HR: 0.41, 95% CI: 0.32–0.53). Similarly, in patients with the EGFR Del19 mutation, afatinib and erlotinib resulted in significantly longer PFS than gefitinib (HR: 0.48 with 95% CI: 0.33–0.71 and HR: 0.54 with 95% CI: 0.36–0.80, respectively). Moreover, afatinib resulted in significantly longer PFS than gefitinib in patients with brain metastasis (HR: 0.53, 95% CI: 0.33–0.87) or ECOG status 0–1 (HR: 0.37, 95% CI: 0.23–0.59). CONCLUSION: This NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0–1, and with baseline brain metastasis. John Wiley & Sons Australia, Ltd 2023-09-22 /pmc/articles/PMC10643796/ /pubmed/37737541 http://dx.doi.org/10.1111/1759-7714.15111 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Chang, Huang‐Chih
Wang, Chin‐Chou
Tseng, Chia‐Cheng
Huang, Kuo‐Tung
Chen, Yu‐Mu
Chang, Yu‐Ping
Lai, Chien‐Hao
Fang, Wen‐Feng
Lin, Meng‐Chih
Chuang, Hung‐Yi
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
title Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
title_full Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
title_fullStr Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
title_full_unstemmed Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
title_short Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
title_sort do patient characteristics affect egfr tyrosine kinase inhibitor treatment outcomes? a network meta‐analysis of real‐world survival outcomes of east asian patients with advanced non‐small cell lung cancer treated with first‐line egfr‐tkis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643796/
https://www.ncbi.nlm.nih.gov/pubmed/37737541
http://dx.doi.org/10.1111/1759-7714.15111
work_keys_str_mv AT changhuangchih dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT wangchinchou dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT tsengchiacheng dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT huangkuotung dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT chenyumu dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT changyuping dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT laichienhao dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT fangwenfeng dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT linmengchih dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis
AT chuanghungyi dopatientcharacteristicsaffectegfrtyrosinekinaseinhibitortreatmentoutcomesanetworkmetaanalysisofrealworldsurvivaloutcomesofeastasianpatientswithadvancednonsmallcelllungcancertreatedwithfirstlineegfrtkis